Contact
searchSearch
HMP Global

News

News
Data on Black/African American and Hispanic/Latino Patients With Relapsing Multiple Sclerosis Receiving Ocrelizumab: CHIMES Trial 
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
Riociguat Emerges as Key Alternative for Nonresponders to Traditional Treatments in Pulmonary Arterial Hypertension
10/25/2024
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the...
10/25/2024
First Report Managed Care
News
Risk of Disease Activity After Discontinuation of Disease-Modifying Drugs for Multiple Sclerosis
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care
News
Subcutaneous Ocrelizumab Shows Noninferiority to Intravenous Administration in Multiple Sclerosis Treatment
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care
News
RSV Vaccine Receives FDA Approval for Adults Under 50
10/24/2024
Pfizer receives FDA approval for Abrysvo, the first RSV vaccine for adults under 50 at risk of lower respiratory tract disease, marking a significant milestone in respiratory health.
Pfizer receives FDA approval for Abrysvo, the first RSV vaccine for adults under 50 at risk of lower respiratory tract disease, marking a significant milestone in respiratory health.
Pfizer receives FDA approval for...
10/24/2024
First Report Managed Care
News
Current Understandings of Disease Mechanisms and Therapeutic Approaches in Multiple Sclerosis
10/23/2024
A comprehensive review of multiple sclerosis causes, forms, and treatments.
A comprehensive review of multiple sclerosis causes, forms, and treatments.
A comprehensive review of...
10/23/2024
First Report Managed Care
News
Analysis Maps Evolution of UTUC Cells
10/23/2024
The molecular characteristics of primary and metastatic tumors in patients with upper tract urothelial carcinoma (UTUC) are mostly stable, suggesting that oncologists may be able to use analyses of primary tumor samples for molecular...
The molecular characteristics of primary and metastatic tumors in patients with upper tract urothelial carcinoma (UTUC) are mostly stable, suggesting that oncologists may be able to use analyses of primary tumor samples for molecular...
The molecular characteristics of...
10/23/2024
First Report Managed Care
News
Advances in Factor IX Therapy Offer New Hope for Hemophilia B Treatment
10/23/2024
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise...
10/23/2024
First Report Managed Care
News
Unified Nomenclature for RNAi Therapeutics Reflects Growing Advances in Gene Silencing
10/23/2024
RNAi therapeutics advance gene silencing with unified nomenclature.
RNAi therapeutics advance gene silencing with unified nomenclature.
RNAi therapeutics advance gene...
10/23/2024
First Report Managed Care
News
Long-Term Study Reveals Sustained Metabolic Adaptation After Gastric Bypass Surgery
10/21/2024
A study published in the International Journal of Obesity found that gastric bypass surgery leads to significant long-term weight loss and metabolic changes, suggesting that maintaining fat-free mass may help sustain metabolic rates...
A study published in the International Journal of Obesity found that gastric bypass surgery leads to significant long-term weight loss and metabolic changes, suggesting that maintaining fat-free mass may help sustain metabolic rates...
A study published in the...
10/21/2024
First Report Managed Care

Behind the Bill

Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations 2.0: New Administration, Same Mission?
01/22/2025
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major...
01/22/2025
First Report Managed Care
Behind the Bill
The First 100 Days: Health Care's Critical Deadlines in 2025
01/15/2025
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces...
01/15/2025
First Report Managed Care
Behind the Bill
Trump's Executive Orders in a Post-Chevron World: Implications for Health Care Policy
01/08/2025
Happy New Year! As we dive into 2025, it’s clear that this year promises to bring significant changes to health care. With President-elect Donald Trump's inauguration just weeks away, the spotlight is already shifting to how his...
Happy New Year! As we dive into 2025, it’s clear that this year promises to bring significant changes to health care. With President-elect Donald Trump's inauguration just weeks away, the spotlight is already shifting to how his...
Happy New Year! As we dive into...
01/08/2025
First Report Managed Care
Behind the Bill
A Tale of Two Congresses—Health Care Policy in the 117th vs 118th
12/18/2024
The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor's transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the...
The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor's transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the...
The 118th Congress is wrapping...
12/18/2024
First Report Managed Care
Behind the Bill
Medicare Privatization Under New CMS Leadership: What's Really at Stake
12/11/2024
After writing about Dr Oz's potential impact on Medicare drug negotiations last week, I found myself diving deeper into an aspect of his nomination that deserves closer attention: his vision for Medicare's future. A letter from Senate...
After writing about Dr Oz's potential impact on Medicare drug negotiations last week, I found myself diving deeper into an aspect of his nomination that deserves closer attention: his vision for Medicare's future. A letter from Senate...
After writing about Dr Oz's...
12/11/2024
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations Under New CMS Leadership
12/04/2024
President-elect Donald Trump nominated Dr Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS). With this potential change in leadership, are there any implications for Medicare’s drug price negotiation program,...
President-elect Donald Trump nominated Dr Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS). With this potential change in leadership, are there any implications for Medicare’s drug price negotiation program,...
President-elect Donald Trump...
12/04/2024
First Report Managed Care
Behind the Bill

When Recess Isn’t a Break: What NLRB v Canning Means for HHS
11/20/2024
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s...
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s...
As Robert F. Kennedy Jr’s...
11/20/2024
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use